CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with China National Pharmaceutical Group Co., Ltd. ("Sinopharm"). The two parties will establish the Sinopharm - Harbour BioMed Innovation Consortium (the "Innovation Consortium") to advance collaborative research and development of innovative biologics. Under the terms of the agreement, Harbour BioMed and Sinopharm will collaborate across the full research and development lifecycle of innovative biologics, with a strategic focus...